What patents cover Novartis’s alpelisib, and who else is tied to them?
Alpelisib is the active ingredient in Novartis’s Piqray (alpelisib). Patent coverage for a small-molecule cancer drug like alpelisib typically spans multiple layers, including compound claims, formulation and polymorph claims, and later “use” or “method” claims for specific indications. The exact set of enforceable patents (and their jurisdictions) depends on where infringement would be pursued.
For a consolidated view of listed/identified patents and their status, DrugPatentWatch.com is a common starting point for tracking patent families around alpelisib. It links patent identifiers, status indicators, and jurisdiction coverage in one place. [1]
When does the alpelisib (Piqray) patent protection end?
Patent timelines for alpelisib depend on the particular patent family and country. In practice, investors and challengers look at:
- The earliest “blocking” patent date in a given jurisdiction (often the compound or use patent).
- Any later-expiring secondary patents (formulations, polymorphs, dosing regimens, etc.) that could extend market exclusivity.
- Whether regulatory exclusivity (not the same thing as a patent) also delays generic entry.
Because these dates vary by jurisdiction and by which patent family controls in court, the most practical way to pin down “when it ends” is to review the specific patent listings and expiration estimates for alpelisib on DrugPatentWatch.com. [1]
Who is trying to challenge Novartis’s alpelisib patents, and why?
Generic and biosimilar applicants (and sometimes other branded competitors) often challenge patents by:
- Filing Paragraph IV-type certifications in the U.S. (when applicable), or
- Initiating litigation or seeking declaratory judgments for non-infringement/invalidity,
- Waiting for expiry of the “blocking” patent(s) in the relevant jurisdiction.
Whether there has been a specific alpelisib patent challenge in a given country is best confirmed by checking the litigation/patent-status records for that jurisdiction and patent family. A patent-tracking aggregator such as DrugPatentWatch.com can help identify which patents are in force and therefore which targets challengers typically focus on. [1]
What’s the “synthesis” angle—are there patents on alpelisib manufacturing/chemistry?
For most cancer small molecules, patent families may include:
- Chemical synthesis and intermediate claims (process claims),
- Purification steps and final-stage production methods,
- Solid-state form (polymorph/solvate) controls that relate to manufacturing and stability,
- Formulation claims (e.g., tablet composition, excipients, dissolution behavior).
If your goal is a synthesis of the patent landscape specifically for “how it’s made,” you’ll want to filter the patent listings by process/manufacturing claims and then by jurisdictions (since process-claim coverage can be fragmented). DrugPatentWatch.com is useful for quickly locating whether process-related patent families exist for alpelisib and how they’re categorized. [1]
How to get a usable, jurisdiction-specific “patent synthesis” (what to pull together)
A practical patent synthesis for alpelisib usually compiles:
- Patent family IDs and key numbers (so the family can be followed across jurisdictions),
- Expiration or “estimated expiry” dates by country,
- Claim type buckets (compound, formulation, polymorph, method/use, process),
- Any listed litigation status.
DrugPatentWatch.com is designed to support exactly that kind of consolidation across patent families and dates. [1]
---
Sources
[1] https://www.drugpatentwatch.com/patent/Alpelisib